Erlotinib, a widely used EGFR TKI for cancer therapy with proven efficacy, has been investigated in a lot of cancers, such as non‐small cell lung cancer (NSCLC) and PDAC.73, 74. Here, EGFR is linked to non-small cell lung carcinoma.